MUM1/IRF4联合β_2微球蛋白检测与外周T细胞淋巴瘤预后的相关性研究  

Association of MUM1/IRF4 and β_2 Microglobulin Detection with Prognosis of Peripheral T-cell Lymphoma

作　　者：张琳[1] 夏建胜[2] 韩方征[2] 董巧凤[2] ZHANG Lin;XIA Jian-sheng;HAN Fang-zheng;DONG Qiao-feng(Taishan Medical College,Tai＇an,Shandong Province,271000 China;Heze Municipal Hospital,Heze,Shandong Province,274000 China)

机构地区：[1]泰山医学院,山东泰安271000 [2]菏泽市立医院,山东菏泽274000

出　　处：《系统医学》2018年第8期145-149,共5页Systems Medicine

摘　　要：目的探讨MUM1/IRF4蛋白、β_2微球蛋白(β_2-MG)联合检测与外周T细胞淋巴瘤(PTCL)的预后相关性。方法回顾性分析2007年1月—2016年12月菏泽市立医院采用CHOP方案治疗的外周T细胞淋巴瘤的临床资料,对MUM1/IRF4、β_2微球蛋白的表达与PTCL预后的关系进行统计学分析。结果 MUMl/IRF4阳性表达者治疗有效率为50.0%(23/46);MUMl/IRF4阴性表达者治疗有效率80.0%(16/20),两者比较差异有统计学意义(χ~2=5.190,P=0.023)。MUM1+/β_2-MG+、MUM1-/β_2-MG+、MUM1+/β_2-MG-、MUM1-/β_2-MG-表达的有效率分别为42.1%、57.1%、87.5%、92.3%,差异有统计学意义(χ~2=13.344,P=0.003)。全组中位OS为16个月(95%CI:12~20个月),中位数OS Mum1/IRF4阴性和Mum1/IRF4阳性组为20和13个月(χ~2=13.442,P=0.000)。进一步比较MUM-1+/β_2-MG+、MUM-1+/β_2-MG-、MUM-1-/β_2-MG+、MUM-1-/β_2-MG-中位数OS分别为13、15、18、20个月,差异有统计学意义(χ~2=19.319,P=0.000)。结论 MUM1/IRF4蛋白在PTCL中过表达提示预后不良,这在同时表达β_2-MG的患者中更显著。MUM1/IRF4和β_2-MG同时高表达可作为判断患者预后的重要指标。Objective This paper tries to investigate the association of MUM1/IRF4 protein and β2-microglobulin（β2-MG） with the prognosis of peripheral T-cell lymphoma（PTCL）. Methods The effective rate of MUMl/IRF4 positive expression was 50.0%（23/46）. The effective rate of MUMl/IRF4 negative expression was 80.0%（16/20）. There was a statistically significant difference between the two groups（χ2=5.190, P = 0.023）. The effective rates of expression of MUM1＋/β2-MG＋, MUM1-/β2-MG＋, MUM1＋/β2-MG-, and MUM1-/β2-MG-were 42.1%, 57.1%, 87.5%, 92.3%, respectively. The difference was statistically significant（χ2=13.344, P=0.003）. The median OS of the whole group was 16 months（95% CI： 1220 months）, and the median OS Mum1/IRF4 negative and Mum1/IRF4 positive groups were 20 and 13 months（χ2=13.442,P=0.000）. Further comparisons of the median OS of MUM-1＋/β2-MG＋, MUM-1＋/β2-MG-,MUM-1-/β2-MG＋, and MUM-1-/β2-MG-were 13, 15, and 18, 20 months, respectively. The difference was statistically significant（χ2=19.319,P=0.000）. Conclusion The overexpression of MUM1/IRF4 protein in PTCL indicates a poor prognosis, which is more pronounced in patients with simultaneous expression of β2-MG. The high expression of MUM1/IRF4 and β2-MG at the same time can be used as an important indicator to determine the prognosis of patients.

关 键 词：淋巴瘤 T细胞 MUMl/IRF4蛋白 Β2微球蛋白 预后 

分 类 号：R828.3[医药卫生—临床医学]